Skip to main content
Clinical Trials/ISRCTN68399350
ISRCTN68399350
Completed
Phase 2

A randomised trial for the Treatment of cardiac AMyloid light-chain amyloidosis with the green tea compound Epigallocatechin-3-gALlate (TAME-AL)

Ruprecht-Karls-University of Heidelberg (Germany)0 sites38 target enrollmentOctober 5, 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Amyloid light-chain amyloidosis
Sponsor
Ruprecht-Karls-University of Heidelberg (Germany)
Enrollment
38
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 5, 2012
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ruprecht-Karls-University of Heidelberg (Germany)

Eligibility Criteria

Inclusion Criteria

  • 1\. Biopsy proven systemic AL amyloidosis
  • 2\. Cardiac involvement with septum thickness \>12 mm (without other causes as published by Gertz et al)
  • 3\. Hypertension or other potential causes of left ventricular hypertrophy
  • 4\. Previously treated with chemotherapy
  • 5\. Induced at least a very good partial remission of the underlying monoclonal plasma cell or B cell disorder

Exclusion Criteria

  • 1\. Age \< 18 years
  • 2\. Concomitant multiple myeloma stage II and III (Salmon and Durie)
  • 3\. Concurrent chemotherapy necessary
  • 4\. Time to last chemotherapy \> 6 months
  • 5\. Chronic liver disease
  • 6\. Bilirubin \> 1,5 mg/dl
  • 7\. Not able to visit Amyloidosis Clinic in Heidelberg every 3 months

Outcomes

Primary Outcomes

Not specified

Similar Trials